Trials / Not Yet Recruiting
Not Yet RecruitingNCT06986057
Iparomlimab and Tuvonralimab Combined With Platinum-Based Chemotherapy for Neoadjuvant Treatment of Cervical Cancer
Iparomlimab and Tuvonralimab (QL1706) Combined With Platinum-Based Chemotherapy for Neoadjuvant Treatment of Cervical Cancer: A Single-Arm Phase II Clinical Trial
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 28 (estimated)
- Sponsor
- Shandong Tumor Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the efficacy and safety of Iparomlimab and tuvonralimab (QL1706) in combination with platinum-based chemotherapy for cervical cancer neoadjuvant therapy. Additionally, the study aims to identify potential predictive biomarkers for therapeutic efficacy by analyzing tumor tissues and peripheral blood samples from participants receiving this combined treatment regimen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Iparomlimab and tuvonralimab (QL1706) combined with platinum-based chemotherapy | Iparomlimab and tuvonralimab (QL1706) combined with platinum-based chemotherapy |
Timeline
- Start date
- 2025-05-31
- Primary completion
- 2026-07-31
- Completion
- 2026-12-31
- First posted
- 2025-05-22
- Last updated
- 2025-05-22
Source: ClinicalTrials.gov record NCT06986057. Inclusion in this directory is not an endorsement.